[144] Quest Diagnostics Inc. SEC Filing

Rhea-AI Filing Summary

Quest Diagnostics insider Thomas P. Plewman filed a Form 144 disclosing a proposed sale of 1,975 common shares (approximate aggregate market value $365,375) to be sold via Fidelity Brokerage Services on the NYSE on 08/21/2025. The shares were acquired on 02/18/2022 upon restricted stock vesting and were received as compensation. The filer also reported three recent sales in August 2025 totaling 12,042 shares for gross proceeds of $2,153,481 (sales on 08/06/2025, 08/15/2025, and 08/19/2025). The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

• Securities were acquired via restricted stock vesting, indicating they were received as compensation rather than external purchases.
• Filer included required attestation that they are not aware of undisclosed material adverse information.

Negative

• Insider sales in August 2025 totaled 12,042 shares for about $2,153,481, showing notable recent dispositions by the filer.
• Planned sale of 1,975 shares (≈$365,375) will further reduce the filer’s holdings.

Insights

Securities Analyst

TL;DR Insider sale disclosed; shares originated from compensation vesting; recent sales total roughly $2.15M.

The filing shows a planned sale of 1,975 Quest Diagnostics (DGX) shares valued at about $365k and confirms those shares were acquired via restricted stock vesting on 02/18/2022 as compensation. The filer also reported three prior August 2025 sales totaling 12,042 shares for approximately $2.15M in gross proceeds. From a market-impact perspective, these disclosures are routine for insiders monetizing vested equity and do not, by themselves, indicate undisclosed company issues. Monitor for any pattern of accelerated disposals, but this single Form 144 reflects ordinary post-vesting sales executed through a brokerage.

Corporate Governance Expert

TL;DR Form 144 documents lawful insider dispositions tied to compensation vesting and includes required seller attestations.

The notice properly identifies the nature of acquisition (restricted stock vesting) and the intended broker (Fidelity Brokerage Services). The seller signed the required attestation regarding lack of undisclosed material information. This filing meets disclosure expectations for insider trades; it does not disclose any governance events, employment changes, or trading-plan dates that would suggest atypical conduct. As always, investors should view such filings in the broader context of ownership levels and historical insider activity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 07094	1975	365375.00	111823441	08/21/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/18/2022	Restricted Stock Vesting	Issuer			1975	02/18/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Thomas P Plewman 500 Plaza Drive Secaucus NJ 07094	Common	08/06/2025	5535	968625.00
Thomas P Plewman 500 Plaza Drive Secaucus NJ 07094	Common	08/15/2025	1975	355500.00
Thomas P Plewman 500 Plaza Drive Secaucus NJ 07094	Common	08/19/2025	4532	829356.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 for Quest Diagnostics (DGX) disclose?

The Form 144 disclosed a proposed sale of 1,975 common shares (≈$365,375) to be sold on 08/21/2025, acquired via restricted stock vesting on 02/18/2022 as compensation.

Who is the seller named in the DGX Form 144?

The seller is Thomas P. Plewman, with trades executed through Fidelity Brokerage Services LLC on the NYSE.

How much did the filer sell in the past three months according to the filing?

The filer reported three sales on 08/06/2025, 08/15/2025, and 08/19/2025 totaling 12,042 shares for gross proceeds of $2,153,481.

Were the shares being sold originally purchased or received as compensation?

The shares were received via restricted stock vesting on 02/18/2022 and the payment nature is listed as compensation.

Does the Form 144 indicate any undisclosed material information about Quest Diagnostics (DGX)?

The filer attested they do not know any material adverse information about the issuer that has not been publicly disclosed.